Published by Erik Greb on December 19, 2011
under Manufacturing, North America News, Regulation, Trends
Drug shortages are increasing at an alarming rate. Between 2005 and 2010, the number of drug shortages per year leapt from 61 to 178. This year’s total, 220 as of October, already surpasses that of last year. Fortunately, FDA has taken a step that is intended to prevent drug shortages from becoming crises. Read more »
Published by Stephanie Sutton, PharmTech Europe on December 16, 2011
under Manufacturing
Earlier this week I read a great article on Reuters about how pharma companies are looking to the automobile industry for innovation by transferring some of the lean methodologies learned in car manufacturing to pharmaceuticals. As a pharmaceutical journalist, I read a lot of news stories and articles about innovative new products, R&D projects and partnerships, and sometimes it’s too easy to let your eyes gloss over these as everyday business. Earlier this year though, the partnership between GlaxoSmithKline the McLaren Group really grabbed my attention. Pharma… and a racing-car maker? That’s definitely not an everyday occurrence. Or is it? Read more »
Published by Angie Drakulich on December 14, 2011
under Trends
This post was written by Eric Langer, Managing Partner, BioPlan Associates, Inc.
Yes, doing surveys is a pain. So there’d better be a darn good reason. Here’s a survey with 7 good reasons that I consider worth the effort. The industry and participants benefit from the 9th Annual Report and Survey of Biopharmaceutical Manufacturing, and here’s why. Read more »
Published by Erik Greb on December 12, 2011
under Manufacturing, North America News, Regulation
Just when it seemed that controversy over the Plan B contraceptive was a thing of the past, the drug returned to the headlines. In an unprecedented action, Health and Human Services Secretary Kathleen Sebelius overruled FDA’s decision to allow Teva’s Plan B One-Step to be sold over the counter to girls under the age of 17. In a public statement, Sebelius said that about 10% of girls can bear children by 11.1 years of age. Teva’s “label comprehension and actual use studies did not contain data for all ages for which this product would be available for use,” she said. But FDA sees the matter differently. Read more »
Published by Rich Whitworth on December 9, 2011
under Biotech, Industry conferences
Just over a week ago, I decided to hop on the early train to Glasgow, Scotland, so that I might catch at least half of the 8th bioProcess UK conference, focusing on advancing next generation therapies. The meeting was held in the very fitting Glasgow Science Center and, given the strikes over public sector pensions that day, there were plenty of youngsters mingling with the crowds—the next generation of bioprocess engineers perhaps? Amazingly, presentations were delivered in the IMAX theatre—I have never seen PowerPoint slides on such a scale before—but given the eminence of some of the keynote speakers involved, it too was quite apt. Read more »
Published by Amy Ritter on December 8, 2011
under Uncategorized
This week’s announcement of a public meeting to discuss a user fee structure for biosimilars marks another step towards implementation of the Biologics Price Competition and Innovation Act of 2009, which mandates that FDA establish an approval pathway for biosimilars. The question on everyone’s mind regarding the definition of a biosimilar has yet to be answered, but the fee announcement and the accompanying proposed review of performance goals and procedures provides some welcome information about what the approval process will look like. Read more »
Published by Patricia Van Arnum on December 6, 2011
under Biotech, Drug Delivery, Formulation, Ingredients, Manufacturing, Outsourcing, Trends
A new year is often reason to reflect on what has occurred and to consider what the future may hold. And for 2012, Pharmaceutical Technology is doing just that. Next year will mark Pharmaceutical Technology’s 35th anniversary, and as part of a special issue to be published in July 2012, we are seeking to gain your input on what you feel have been the most noteworthy achievements in the pharmaceutical sciences and manufacturing and what future developments may shape the industry. Read more »
Published by Erik Greb on December 5, 2011
under Manufacturing, North America News, Regulation, Trends
The day of reckoning is here. As patent protection expires for top-selling drugs, some firms are scrambling to stay one step ahead of generic-drug competitors. As Amy Ritter wrote last week, Pfizer is drawing scrutiny by asking pharmacy benefit managers to block pharmacies from filling prescriptions with generic alternatives to Lipitor, in exchange for a discount on the product. Rep. John Sarbanes (D-MD) asked the Federal Trade Commission to take action against this arrangement, but another tactic is also causing concern. Read more »
Published by Stephanie Sutton, PharmTech Europe on December 2, 2011
under Information Technology
We love social media here at PharmTech.com, but many pharma companies have been wary about how to make the most of these new communication platforms—and understandably so given that last year Novartis received an FDA warning letter about a Facebook widgit on its website.
One pharma company that does seem to love social media though is Germany-based Merck KGaA—so much so that the company was prepared to go to court when its Facebook page was recently taken over by US rival Merck & Co. Read more »
Published by Amy Ritter on December 1, 2011
under North America News, Products
On Nov. 30, 2011, the patent for Lipitor, the cholesterol-lowering drug that defined the term “blockbuster,” expired. Over its lifetime, it is estimated that Lipitor generated over $100 billion in sales for its parent company, Pfizer, since its introduction in 1997. Read more »
« Previous Page — Next Page »